Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, January 29th. Analysts expect the company to ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Under the terms of the agreement, Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name AHZANTIVE ®3, subject to regulatory approval. In return, ...